These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2363946)

  • 1. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin).
    Eksborg S
    Acta Oncol; 1990; 29(3):339-42. PubMed ID: 2363946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
    Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.
    Eksborg S; Hardell L; Bengtsson NO; Sjödin M; Elfsson B
    Med Oncol Tumor Pharmacother; 1992; 9(2):75-80. PubMed ID: 1341719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in human plasma by high-performance liquid chromatography and electrochemical detection.
    Ricciarello R; Pichini S; Pacifici R; Altieri I; Pellegrini M; Fattorossi A; Zuccaro P
    J Chromatogr B Biomed Sci Appl; 1998 Apr; 707(1-2):219-25. PubMed ID: 9613953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.
    Tidefelt U; Sundman-Engberg B; Paul C
    Cancer Chemother Pharmacol; 1989; 24(4):225-9. PubMed ID: 2752502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of anthracyclines.
    Eksborg S
    Acta Oncol; 1989; 28(6):873-6. PubMed ID: 2611038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
    Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
    J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
    El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
    J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
    J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
    Jakobsen P; Bastholt L; Dalmark M; Pfeiffer P; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS; Mouridsen HT
    Cancer Chemother Pharmacol; 1991; 28(6):465-9. PubMed ID: 1934250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients.
    Andersen A; Holte H; Slørdal L
    Cancer Chemother Pharmacol; 1999; 44(5):422-6. PubMed ID: 10501917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.
    van der Vijgh WJ; Maessen PA; Pinedo HM
    Cancer Chemother Pharmacol; 1990; 26(1):9-12. PubMed ID: 2322993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy.
    Barker IK; Crawford SM; Fell AF
    J Chromatogr B Biomed Appl; 1996 Jun; 681(2):323-9. PubMed ID: 8811443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
    Gurney HP; Ackland S; Gebski V; Farrell G
    J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy.
    Knobloch K; Tepe J; Rossner D; Lichtinghagen R; Luck HJ; Busch KH; Vogt PM
    Int J Cardiol; 2008 Aug; 128(3):316-25. PubMed ID: 17707098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.